Acalabrutinib May Reduce Toxicity in Chronic Lymphocytic Leukemia Compared With Ibrutinib
Researchers sought to determine whether acalabrutinib may lower the rate of treatment-related AEs while maintaining a similar PFS in patients with CLL.
All articles by Jonathan Goodman, MPhil
Consolidation Therapy in Newly Diagnosed PCNSL Remains Undefined
Researchers sought to determine whether myeloablative consolidation after induction therapy would improve PFS in patients with newly diagnosed primary central nervous system lymphoma.
Phase 3 Trial Evaluating Venetoclax, Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes
Researchers are conducting a randomized phase 3 trial evaluating the safety and efficacy of venetoclax with azacitidine among patients with previously untreated, higher-risk MDS.
Adding Ixazomib to Dexamethasone Does Not Improve PFS Compared to Pomalidomide in Multiple Myeloma
Researchers sought to determine whether doublet therapy with dexamethasone and ixazomib would improve survival in patients with multiple myeloma compared with pomalidomide.
Patients With Acute Myeloid Leukemia May Have Suboptimal Outcomes Because of Fears of Treatment Side Effects
Researchers sought to determine whether patients with AML were being undertreated due to patient fear about side effects to treatment.
Enasidenib With Azacitidine May Improve Survival in Patients With IDH2-Mutated Myelodysplastic Syndrome
Researchers sought to determine whether enasidenib combined with azacitidine may increase survival in patients with IDH2-mutated myelodysplastic syndrome.
Phase 4 Feasibility Trial Is Evaluating At-Home Treatment of MRD-Positive BCP-ALL
Researchers are running a phase 4 feasibility trial to determine the safety and effectiveness of at-home blinatumomab treatment in patients with MRD-positive B cell precursor ALL.
Aspacytarabine Is Safe, Effective in First-Line Acute Myeloid Leukemia
Researchers sought to determine whether first-line aspacytarabine would be safe and effective in patients with AML who cannot tolerate chemotherapy.
Maintenance With Ixazomib Not Recommended for Patients With Multiple Myeloma Undergoing Allogeneic HCT
Researchers sought to determine whether giving maintenance ixazomib to patients with multiple myeloma who undergo allogeneic hematopoietic stem cell transplantation would have a clinical benefit.
KTE-X19 Shows Promising Efficacy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Researchers sought to determine whether KTE-X19, a CAR-T cell therapy, would be effective in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
